secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-04-01T23:59:59+00:00
Accession:  0001493152-22-008679
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo doses >50% of subjects in Phase 2 trial for acute cannabinoid intoxication; expects IND by end of 2022
--------------------------------------------------------------------------------

- Dosed more than half of the 60 planned subjects in Part A of Phase 2 trial for ANEB-001 at CHDR in Netherlands.
- Top-line data for Part A expected by end of H1 2022.
- Plan to include Part A data in IND submission to FDA; expects to file IND before end of 2022.
- CEO Simon Allen states robust enrollment enables smoother bridge to U.S. trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222008679/0001493152-22-008679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222008679/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-008679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer